<div id="readability-page-1"><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) is expected to be issuing its  Q1 2025 quarterly earnings data before the market opens  on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $79.17 billion for the quarter.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><ul><li>Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY</li></ul><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%.  On average, analysts expect Novo Nordisk A/S to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year. </p><h2>Novo Nordisk A/S Trading Up 4.0 %</h2><p>Shares of NVO opened at $65.12 on Wednesday. The stock's 50-day moving average is $72.84 and its two-hundred day moving average is $88.85. The stock has a market cap of $292.23 billion, a PE ratio of 19.79, a P/E/G ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. </p><h2>Novo Nordisk A/S Increases Dividend</h2><ul><li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li></ul><p>The firm also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend  was Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's payout ratio is 49.54%. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several research analysts recently commented on the company. BMO Capital Markets  reiterated a &#34;market perform&#34; rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. StockNews.com upgraded Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday, April 25th. Dbs Bank cut Novo Nordisk A/S to a &#34;sell&#34; rating in a research note on Friday, April 25th. Stifel Nicolaus cut Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, March 3rd. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, five have issued  a hold rating, five have assigned  a buy rating and one  has assigned  a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of &#34;Hold&#34; and an average target price of $135.00.</p><ul><li>Which Healthcare Stock Is the Best Buy Right Now?</li></ul><p><b>Check Out Our Latest Stock Report on NVO</b></p><h2>Hedge Funds Weigh In On Novo Nordisk A/S</h2><p>An institutional investor recently raised its position in Novo Nordisk A/S stock. Revolve Wealth Partners LLC grew its stake in shares of  Novo Nordisk A/S (NYSE:NVO - Free Report) by 8.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,490 shares of the company's stock after purchasing an additional 200 shares during the quarter. Revolve Wealth Partners LLC's holdings in Novo Nordisk A/S were worth $214,000 as of its most recent SEC filing. Institutional investors and hedge funds own  11.54% of the company's stock. </p><h2>Novo Nordisk A/S Company Profile</h2> (Get Free Report)<p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li><li>Expert Stock Trading Psychology Tips</li><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li><li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li><li>Coca-Cola Company Stock Can Bubble to New Highs This Year</li><li>Insider Buying Explained: What Investors Need to Know</li><li>3 Stocks Lifting 2025 Guidance Despite Market Jitters</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Novo Nordisk A/S (NYSE:NVO) is set to release its Q1 2025 earnings on May 7, with analysts predicting earnings of $0.92 per share and revenue of $79.17 billion. The company recently declared a semi-annual dividend of $0.7874, up from $0.51, with a yield of 1.2%. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $135.00. Institutional investors own 11.54% of the company, and the stock is currently trading at $65.12, down from a 12-month high of $148.15.</p>

Novo Nordisk A/S (NVO) to Release Quarterly Earnings on Wednesday